Combination ART Regimen Associated With Low Rates Of Viremic Events Among Patients With HIV, Study Finds

Infectious Disease Advisor (6/20, Nye) reported an analysis found that “the 3-drug antiretroviral therapy (ART) regimen bictegravir/emtricitabine/tenofovir alafenamide is associated with low rates of viremic events among patients with HIV infection, especially for those with high-level treatment adherence.” The analysis “comprised patient data captured from 8 randomized controlled phase 3/3b trials.” The researchers identified “a total of 411 viremic events occurred among the study population” who initiated the 3-drug ART regimen. They noted that “of patients who experienced viremia, 75.5% had a single event, 16.9% had 2 events, and 7.6% had 3 or more events. The median time to first viremic event was 254 days. Further analysis of patients who experienced viremia indicated most (86.2%) subsequently achieved resuppression.” Overall, “the researchers observed significantly increased rates of high-level treatment adherence (<85%) among patients with vs without a viremic event recorded during the study period.” The study was published in Infectious Diseases and Therapy.